Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China.
Asia Pac J Clin Oncol. 2021 Dec;17(6):454-461. doi: 10.1111/ajco.13466. Epub 2020 Oct 20.
Primary squamous cell carcinoma of the breast (PSCCB) is a rare clinical classification of breast tumors. Little is known about its clinicopathological features, prognosis and potential therapeutic strategies. The purpose of this study is to evaluate the effect of postoperative radiotherapy (PORT) on patients with squamous cell carcinoma (SCC) of the breast.
We retrospectively analyzed patients diagnosed with PSCCB in our center. All pathological slides were reviewed by an experienced pathologist to confirm the diagnosis. Furthermore, we searched the public database for patients with SCC of the breast. Then, we analyzed the clinicopathological features, treatment methods and patient outcomes.
We identified 14 patients with primary SCC of the breast in our center. Additionally, 739 patients with SCC of the breast from the Surveillance, Epidemiology and End Results (SEER) database were diagnosed between 1975 and 2016. Only 453 patients who underwent surgery were included in this study. Patients from the SEER database had a more advanced tumor node metastasis (TNM) stage than patients from our center. The median overall survival (OS) of all patients was 104 months (95% confidence interval [CI], 87.2-120.8 months), and the 5-year OS was 60.8% (95% CI, 56.1%-65.5%). Most of the patients (58%) tested negative for hormonal receptor expression. Multivariate analysis showed that PORT was an independent prognostic factor for OS.
The results of our study demonstrate that SCC of the breast presents aggressive behavior with unique clinical characteristics. PORT improved OS significantly in patients with SCC of the breast. Longer-term studies are needed to confirm our findings.
乳腺原发性鳞状细胞癌（PSCCB）是一种罕见的乳腺肿瘤临床分类。关于其临床病理特征、预后和潜在治疗策略知之甚少。本研究旨在评估术后放疗（PORT）对乳腺鳞状细胞癌（SCC）患者的疗效。
我们回顾性分析了在我院诊断为 PSCCB 的患者。所有病理切片均由经验丰富的病理学家进行复查以确认诊断。此外，我们还在公共数据库中搜索了乳腺 SCC 患者。然后，我们分析了临床病理特征、治疗方法和患者结局。
我们在我院确定了 14 例原发性乳腺 SCC 患者。此外，1975 年至 2016 年期间，SEER 数据库中诊断出 739 例乳腺 SCC 患者。本研究仅纳入了接受手术治疗的 453 例患者。SEER 数据库中的患者肿瘤淋巴结转移（TNM）分期比我院的患者更晚。所有患者的中位总生存期（OS）为 104 个月（95%置信区间 [CI]，87.2-120.8 个月），5 年 OS 为 60.8%（95% CI，56.1%-65.5%）。大多数患者（58%）的激素受体表达为阴性。多因素分析显示 PORT 是 OS 的独立预后因素。
本研究结果表明，乳腺 SCC 具有侵袭性行为和独特的临床特征。PORT 可显著改善乳腺 SCC 患者的 OS。需要进一步的长期研究来证实我们的研究结果。
